Chapter 1. Introduction


1.1. Report description and scope

1.2. Research scope

1.3. Research methodology


1.3.1. Market research process

1.3.2. Market research methodology

Chapter 2. Executive Summary


2.1. Global leukemia therapeutics market, 2016 2022 (USD Billion)

2.2. Global leukemia therapeutics market : Snapshot

Chapter 3. Leukemia therapeutics Market Dynamics


3.1. Introduction

3.2. Market drivers


3.2.1. Global leukemia therapeutics market drivers: Impact analysis

3.2.2. Novel drug discovery approaches

3.2.3. Growing incidence rate of target disease

3.3. Market restraints


3.3.1. Global leukemia therapeutics market restraints: Impact analysis

3.3.2. High treatment cost

3.4. Opportunities


3.4.1. Increasing healthcare expenditure

3.5. Porters five forces analysis


3.5.1. Bargaining power of suppliers

3.5.2. Bargaining power of buyers

3.5.3. Threat from new entrants

3.5.4. Threat from new substitutes

3.5.5. Degree of competition

3.6. Market attractiveness analysis


3.6.1. Market attractiveness analysis, by type segment

3.6.2. Market attractiveness analysis, by therapy segment

3.6.3. Market attractiveness analysis, by regional segment

Chapter 4. Global Leukemia therapeutics Market Competitive Landscape


4.1. Company Market Share Analysis


4.1.1. Global leukemia therapeutics market: company market share, 2015

4.2. Strategic Development


4.2.1. Acquisitions Mergers

4.2.2. New Therapy Launch

4.2.3. Agreements, Partnerships, Collaborations and Joint Ventures

4.2.4. Research and Development, Therapy and Regional Expansion

Chapter 5. Global Leukemia Therapeutics Market Type Segment Analysis


5.1. Global leukemia therapeutics market: Type overview


5.1.1. Global leukemia therapeutics market revenue share, by Type, 2014 and 2022

5.2. Chronic Leukemia


5.2.1. Global leukemia therapeutics market, For chronic leukemia, 2014 2022(USD Billion)

5.3. Acute Leukemia


5.3.1. Global leukemia therapeutics market, For acute leukemia, 2014 2022(USD Billion)

5.4. Other


5.4.1. Global leukemia therapeutics market, For Other, 2014 2022(USD Billion)

Chapter 6. Global Leukemia therapeutics Market Therapy Segment Analysis


6.1. Global leukemia therapeutics market: Therapy overview


6.1.1. Global leukemia therapeutics market revenue share, by Therapy, 2014 and 2022

6.2. Chemotherapy


6.2.1. Global leukemia therapeutics market, For chemotherapy, 2014 2022(USD Billion)

6.3. Biological therapy


6.3.1. Global leukemia therapeutics market, For biological therapy, 2014 2022(USD Billion)

6.4. Radiation therapy


6.4.1. Global leukemia therapeutics market, For radiation therapy, 2014 2022(USD Billion)

6.5. Targeted Therapy


6.5.1. Global leukemia therapeutics market, For targeted therapy, 2014 2022(USD Billion)

6.6. Other


6.6.1. Global leukemia therapeutics market, For other therapy, 2014 2022(USD Billion)

Chapter 7. Global Leukemia therapeutics Market Regional Segment Analysis


7.1. Global leukemia therapeutics market: Regional overview


7.1.1. Global leukemia therapeutics market revenue share, by region, 2014 and 2022

7.2. North America


7.2.1. North America leukemia therapeutics market revenue, by Type, 2014 2022(USD Billion)

7.2.2. North America leukemia therapeutics market revenue, by Therapy, 2014 2022(USD Billion)

7.2.3. U.S.


7.2.3.1. U.S. leukemia therapeutics market revenue, by Type, 2014 2022(USD Billion)

7.2.3.2. U.S. leukemia therapeutics market revenue, by Therapy, 2014 2022(USD Billion)

7.3. Europe


7.3.1. Europe leukemia therapeutics market revenue, by Type, 2014 2022(USD Billion)

7.3.2. Europe leukemia therapeutics market revenue, by Therapy, 2014 2022(USD Billion)

7.3.3. U.K.


7.3.3.1. U.K. leukemia therapeutics market revenue, by Type, 2014 2022(USD Billion)

7.3.3.2. U.K. leukemia therapeutics market revenue, by Therapy, 2014 2022(USD Billion)

7.3.4. Germany


7.3.4.1. Germany leukemia therapeutics market revenue, by Type, 2014 2022(USD Billion)

7.3.4.2. Germany leukemia therapeutics market revenue, by Therapy, 2014 2022(USD Billion)

7.3.5. France


7.3.5.1. France leukemia therapeutics market revenue, by Type, 2014 2022(USD Billion)

7.3.5.2. France leukemia therapeutics market revenue, by Therapy, 2014 2022(USD Billion)

7.4. Asia Pacific


7.4.1. Asia Pacific leukemia therapeutics market revenue, by Type, 2014 2022(USD Billion)

7.4.2. Asia Pacific leukemia therapeutics market revenue, by Therapy, 2014 2022(USD Billion)

7.4.3. Japan


7.4.3.1. Japan leukemia therapeutics market revenue, by Type, 2014 2022(USD Billion)

7.4.3.2. Japan leukemia therapeutics market revenue, by Therapy, 2014 2022(USD Billion)

7.4.4. China


7.4.4.1. China leukemia therapeutics market revenue, by Type, 2014 2022(USD Billion)

7.4.4.2. China leukemia therapeutics market revenue, by Therapy, 2014 2022(USD Billion)

7.4.5. India


7.4.5.1. India leukemia therapeutics market revenue, by Type, 2014 2022(USD Billion)

7.4.5.2. India leukemia therapeutics market revenue, by Therapy, 2014 2022(USD Billion)

7.5. Latin America


7.5.1. Latin America leukemia therapeutics market revenue, by Type, 2014 2022(USD Billion)

7.5.2. Latin America leukemia therapeutics market revenue, by Therapy, 2014 2022(USD Billion)

7.5.3. Brazil


7.5.3.1. Brazil leukemia therapeutics market revenue, by Type, 2014 2022(USD Billion)

7.5.3.2. Brazil leukemia therapeutics market revenue, by Therapy, 2014 2022(USD Billion)

7.6. Middle East and Africa


7.6.1. Middle East and Africa leukemia therapeutics market revenue, by Type, 2014 2022(USD Billion)

7.6.2. Middle East and Africa leukemia therapeutics market revenue, by Therapy, 2014 2022(USD Billion)

Chapter 8. Company Profile


8.1. F. Hoffmann-La Roche Ltd.


8.1.1. Overview

8.1.2. Financials

8.1.3. Therapy portfolio

8.1.4. Business strategy

8.1.5. Recent developments

8.2. Amgen


8.2.1. Overview

8.2.2. Financials

8.2.3. Therapy portfolio

8.2.4. Business strategy

8.2.5. Recent developments

8.3. Bristol-Myers Squibb


8.3.1. Overview

8.3.2. Financials

8.3.3. Therapy portfolio

8.3.4. Business strategy

8.3.5. Recent developments

8.4. Novartis International AG.


8.4.1. Overview

8.4.2. Financials

8.4.3. Therapy portfolio

8.4.4. Business strategy

8.4.5. Recent developments

8.5. Pfizer


8.5.1. Overview

8.5.2. Financials

8.5.3. Therapy portfolio

8.5.4. Business strategy

8.5.5. Recent developments

8.6. Teva Pharmaceuticals


8.6.1. Overview

8.6.2. Financials

8.6.3. Therapy portfolio

8.6.4. Business strategy

8.6.5. Recent developments

8.7. GlaxoSmithKline plc.


8.7.1. Overview

8.7.2. Financials

8.7.3. Therapy portfolio

8.7.4. Business strategy

8.7.5. Recent developments

8.8. Genzyme Corporation


8.8.1. Overview

8.8.2. Financials

8.8.3. Therapy portfolio

8.8.4. Business strategy

8.8.5. Recent developments

8.9. AbbVie Inc.


8.9.1. Overview

8.9.2. Financials

8.9.3. Therapy portfolio

8.9.4. Business strategy

8.9.5. Recent developments

8.10. ARIAD Pharmaceuticals, Inc.


8.10.1. Overview

8.10.2. Financials

8.10.3. Therapy portfolio

8.10.4. Business strategy

8.10.5. Recent developments